Yanqiu Zhang

State Key Laboratory Of Natural Medicines
Nanjing, 211198, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Lycorine alleviates intrahepatic cholestasis by regulating bile acid metabolism via TKT/ATF3/BSEP pathway.

Lycorine alleviates intrahepatic cholestasis by regulating bile acid metabolism via TKT/ATF3/BSEP pathway.

Journal: European journal of pharmacology

Published: May 20, 2026

Ligustilide and tectoridin from Danggui Buxue Decoction synergistically attenuate atherosclerosis by targeting the CD36/TRPM2 axis and TNF-α/NF-κB pathway.

Ligustilide and tectoridin from Danggui Buxue Decoction synergistically attenuate atherosclerosis by targeting the CD36/TRPM2 axis and TNF-α/NF-κB pathway.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: April 15, 2026

Micranthin B alleviates metabolic dysfunction-associated steatohepatitis by targeting G3BP1 to improve stress granule-mediated endoplasmic reticulum stress.

Micranthin B alleviates metabolic dysfunction-associated steatohepatitis by targeting G3BP1 to improve stress granule-mediated endoplasmic reticulum stress.

Journal: Chinese journal of natural medicines

Published: October 23, 2025

Nodosin alleviates cholestatic liver injury by activation of SIRT1/FXR signaling pathway and inhibition of hepatic inflammation.

Nodosin alleviates cholestatic liver injury by activation of SIRT1/FXR signaling pathway and inhibition of hepatic inflammation.

Journal: Biochemical pharmacology

Published: February 21, 2025

Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis.

Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis.

Journal: Cell death & disease

Published: December 10, 2024

LIX1L aggravates MASH-HCC progression by reprogramming of hepatic metabolism and microenvironment via CD36.

LIX1L aggravates MASH-HCC progression by reprogramming of hepatic metabolism and microenvironment via CD36.

Journal: Pharmacological research

Published: October 08, 2024

MKK4 inhibitor: the hope for liver failure prevention and potential small liver graft transplantation.

MKK4 inhibitor: the hope for liver failure prevention and potential small liver graft transplantation.

Journal: Chinese journal of natural medicines

Published: March 28, 2024

Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma.

Lefamulin Overcomes Acquired Drug Resistance via Regulating Mitochondrial Homeostasis by Targeting ILF3 in Hepatocellular Carcinoma.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: February 20, 2024

RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.

RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling.

Journal: Hepatology (Baltimore, Md.)

Published: April 13, 2022

LIX1-like protein drives hepatic stellate cell activation to promote liver fibrosis by regulation of chemokine mRNA stability.

LIX1-like protein drives hepatic stellate cell activation to promote liver fibrosis by regulation of chemokine mRNA stability.

Journal: Signal transduction and targeted therapy

Published: December 27, 2020

Physalin B attenuates liver fibrosis via suppressing LAP2α-HDAC1-mediated deacetylation of the transcription factor GLI1 and hepatic stellate cell activation.

Physalin B attenuates liver fibrosis via suppressing LAP2α-HDAC1-mediated deacetylation of the transcription factor GLI1 and hepatic stellate cell activation.

Journal: British journal of pharmacology

Published: December 01, 2020

LIX1-like protein promotes liver cancer progression via miR-21-3p-mediated inhibition of fructose-1,6-bisphosphatase.

LIX1-like protein promotes liver cancer progression via miR-21-3p-mediated inhibition of fructose-1,6-bisphosphatase.

Journal: Acta pharmaceutica Sinica. B

Published: November 03, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026